Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia

被引：0
|
作者：
Ramona Wullenkord
Christian Reicherts
Jan-Henrik Mikesch
Julia Marx
Klaus Wethmar
Jörn Albring
Simon Call
Georg Lenz
Matthias Stelljes
机构：
[1] University of Münster,Department of Medicine A, Hematology and Oncology
来源：
Annals of Hematology | 2021年 / 100卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：587 / 589
页数：2
相关论文
共 50 条
  • [1] Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
    Wullenkord, Ramona
    Reicherts, Christian
    Mikesch, Jan-Henrik
    Marx, Julia
    Wethmar, Klaus
    Albring, Joern
    Call, Simon
    Lenz, Georg
    Stelljes, Matthias
    ANNALS OF HEMATOLOGY, 2021, 100 (02) : 587 - 589
  • [2] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ueda, Tomoaki
    Fukushima, Kentaro
    Kusakabe, Shinsuke
    Yoshida, Koki
    Suga, Makiko
    Nakai, Ritsuko
    Koike, Midori
    Hino, Akihisa
    Akuta, Keigo
    Toda, Jun
    Nagate, Yasuhiro
    Doi, Yukiko
    Fujita, Jiro
    Yokota, Takafumi
    Hosen, Naoki
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [3] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Yang, Tingting
    Dong, Yetian
    Zhang, Mingming
    Feng, Jingjing
    Fu, Shan
    Xiao, Pingnan
    Hong, Ruimin
    Xu, Huijun
    Cui, Jiazhen
    Huang, Simao
    Wei, Guoqing
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    BLOOD, 2024, 144 : 2819 - 2819
  • [4] A Case in Which Relapsed Acute Lymphoblastic Leukemia was Treated With Blinatumomab and Inotuzumab Ozogamicin in A Down's Syndrome Patient
    Ono, Takahiro
    Akiyama, Kosuke
    Takamido, Shotaro
    Yamaoka, Daishiro
    Takagi, Toshiyuki
    Ujiie, Gakuto
    Kanazawa, Takeru
    Kaneko, Ryota
    Okamoto, Naoko
    Koganesawa, Masaya
    Fujita, Sachio
    Ogawa, Rei
    Suzuki, Manabu
    Matsuno, Ryosuke
    Toyama, Daisuke
    Fujimoto, Yoko
    Ikeda, Hirokazu
    Yamamoto, Shohei
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S28 - S29
  • [5] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Irina Proskorovsky
    Yun Su
    Kyle Fahrbach
    Erik Vandendries
    Véronique Pagé
    Uchenna Onyekwere
    Yunyang Wang
    Joseph C. Cappelleri
    Matthias Stelljes
    Advances in Therapy, 2019, 36 : 2147 - 2160
  • [6] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Proskorovsky, Irina
    Su, Yun
    Fahrbach, Kyle
    Vandendries, Erik
    Page, Veronique
    Onyekwere, Uchenna
    Wang, Yunyang
    Cappelleri, Joseph C.
    Stelljes, Matthias
    ADVANCES IN THERAPY, 2019, 36 (08) : 2147 - 2160
  • [7] Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia
    Ohana, Zahava
    Serraes, Samantha
    Elder, Christopher
    Katusa, Nikolina
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (05) : 1269 - 1275
  • [8] Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy
    Huang, Si-Man
    Wan, Chao-Ling
    Cao, Han-Yu
    Li, Yan-Yan
    Qian, Chong-Sheng
    Zhou, Hai-Xia
    Xu, Ming-Zhu
    Hu, Xiao-Hui
    Dai, Lan
    Dai, Hai-Ping
    Xue, Sheng-Li
    CLINICAL CASE REPORTS, 2023, 11 (12):
  • [9] CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia
    Maus, Marcela V.
    LANCET, 2021, 398 (10299): : 466 - 467
  • [10] Inotuzumab Ozogamicin, a Nonchemotherapy Option for Relapsed Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 268 - 270
12345